Help Patients Stick With a Statin...Instead of the New PCSK9 inhibitors

October 2015

The new PCSK9 inhibitor, Repatha (rih-PATH-ah, evolocumab), will raise questions about how to help patients stick with a statin.

Repatha is similar to Praluent (alirocumab).

Both PCSK9 inhibitors are injectable biologics...may lower LDL about 60%...cost about $14,000/yr...and lack long-term outcome and safety data.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology Help Patients Stick With a Statin...Instead of the New PCSK9 inhibitors
Anticoagulants Use a Checklist to Monitor Patients on DOACs
Testosterone Educate Men About Risks of Testosterone for "Low T"
Women's Health Pick Your Go-To Oral Contraceptive to Simplify Choices
HIV & AIDS Avoid Some HIV Drugs With Simvastatin or Lovastatin
Oral Health Don't Use Antibiotics Before Dental Work for Prosthetic Joint Patients
Biosimilars Explain That Biosimilars are not Exact Generic Equivalents
Vaccines Be Aware that Bexsero and Trumenba Only Protect Against Meningitis B
Substance Use Disorder Be Alert to Unexpected Drugs of Abuse...Such as Bupropion
Diabetes Listen for Gliptin Patients Complaining of Severe Joint Pain
Sexual Dysfunction Don't Use Addyi for Many Women With Sexual Dysfunction
Interactions Watch for Hypoglycemia in Patients Taking Repaglinide Plus Clopidogrel